Value of molecular monitoring during the treatment of chronic myeloid leukemia: A Cancer and Leukemia Group B study

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 26-36

  Stock, W ^a   Westbrook, C A ^a   Peterson, B ^a   Arthur, D C ^a   Szatrowski, T P ^a   Silver, R T ^a   Sher, D A ^a   Wu, D ^a   Le Beau, M M ^a   Schiffer, C A ^a   Bloomfield, C D ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYTARABINE;

ADULT; AGED; ARTICLE; CHRONIC MYELOID LEUKEMIA; DIAGNOSTIC VALUE; FEMALE; GENE REARRANGEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MONITORING; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING;

EID: 0031034771     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.26     Document Type: Article

References (25)

1. Talpaz M, Kantarjian HM, McCredie K, et al: Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome positive patients. Ann Intern Med 114:532-538, 1991
2. Ozer H, George SL, Schiffer CA, et al: Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: Effect of remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82:2975-2984, 1993
3. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820-825, 1994
4. Groffen J, Stephenson JR, Heisterkamp N, et al: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36:93-99, 1984
5. Kurzrock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 319:990-998, 1988
6. Grossman A, Silver RT, Szatrowski TP, et al: Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myelogenous leukemia. Leukemia 5:540-547, 1991
7. Ayscue LH, Ross DW, Ozer H, et al: BCR/ABL recombinant DNA analysis versus karyotype in the diagnosis and therapeutic monitoring of chronic myeloid leukemia. Am J Clin Pathol 94:404-409, 1990
8. Lee MS, Chang KS, Freireich EJ, et al: Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction. Blood 72:893-897, 1988
9. Westbrook CA, Hooberman AL, Spino C, et al: Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia. A Cancer and Leukemia Group B study (8762). Blood 80:2983-2990, 1992
10. Bartram CR, Kleihauer E, DeKlein A, et al: C-abl and bcr are rearranged in a Ph negative CML patient. EMBO J 4:683-686, 1985
11. Westbrook CA, Rubin CM, Carino JJ, et al: Long-range mapping of the Philadelphia chromosome by pulsed-field gel electrophoresis. Blood 71:697-670, 1988
12. Chomczyinski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156-159, 1987
13. Westbrook CA, Chmura SJ, Arenas RB, et al: Human APC gene expression in rodent colonie epithelium in vivo using liposomal gene delivery. Hum Molec Genetics 3:2005-2010, 1994
14. Mitelman F (ed): ISCN: Guideline for Cancer Cytogenetics: Supplement to an International System for Human Cytogenetic Nomenclature VI. Basel, Switzerland, Karger, 1991
15. Lee J, Koh D, Ong CN: Statistical agreement between two methods for measuring a quantitative variable. Compar Biol Med 19:61-70, 1989
16. Fleiss JL: Statistical Methods for Rates and Proportions. New York, NY, Wiley, 1973
17. Kantarjian HM, Deisseroth A, Kurzrock R, et al: Chronic myelogenous leukemia: A concise update. Blood 82:691-703, 1993
18. The Italian Cooperative Study Group on Chronic Myeloid Leukemia: Alpha interferon versus chemotherapy in chronic myeloid leukemia: Updating the Italian study. Blood 84:153a, 1994 (suppl 1, abstr)
19. Stock W, Westbrook C, Peterson B, et al: Molecular monitoring of bcr/abl fusion gene in chronic myelogenous leukemia: Peripheral blood analysis is comparable to a bone marrow examination. Blood 82:331a, 1993 (suppl 1, abstr)
20. Verschraegen CF, Talpaz M, Hirsch-Ginsberg CF, et al: Quantification of the breakpoint cluster region rearrangement for clinical monitoring in Philadelphia chromosome-positive chronic myeloid leukemia. Blood 85:2705-2710, 1995
21. Opalka B, Wandl UB, Becher R, et al: Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alfa-2b alone or in combination with interferon gamma. Blood 78:2188-2193, 1991
22. Lee M-S, Kantarjian, H, Talpaz M, et al: Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy. Blood 79:1920-1923, 1992
23. Roth MS, Antin JH, Ash R, et al: Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood 79:276-282, 1992
24. Cross NCP, Lin F, Chase A, et al: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82:1929-1936, 1993
25. vanRhee F, Lin F, Cullis JO, et al: Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: The case for giving donor leukocyte transfusions before the onset of hematologic relapse. Blood 83:3377-3383, 1993